TAVR was associated with higher early mortality (≤90 days) compared to matched controls (HR 3.90; 95% CI 2.82-5.39; p<0.001), but late mortality (>90 days) was similar between groups.
Cohort (n=16,042)
Does survival in aortic stenosis patients treated with TAVR differ from an age- and sex-matched background population?
Aortic stenosis patients who survive the first three months after TAVR have a similar long-term survival rate to an age- and sex-matched general population, particularly those with low-to-intermediate risk and high transvalvular gradients.
Hazard Ratio: 3.9 (95% CI 2.82–5.39)
p-value: p=<0.001
AIMS: This study aimed to assess survival and causes of death in a real-world TAVR population as compared to an age- and sex-matched background population. METHODS AND RESULTS: Each aortic stenosis (AS) patient treated with TAVR in Eastern Denmark between 2007 and 2014 (n=617) was matched with 25 age- and sex-matched controls (n=15,425) randomly drawn from the general Danish population. In the total TAVR population, early mortality (≤90 days) was significantly higher (hazard ratio HR 3.90 2.82-5.39; p90 days) was not different between the TAVR and background population (HR 1.16 0.96-1.40; p=0.126), causes of death being mainly non-CV. In subgroup analysis, the HR for late mortality was 0.98, 1.11, and 1.90 for the low-, intermediate-, and high-risk TAVR groups, respectively, as compared to their matched controls and 1.04, 1.45, and 1.52 for the high gradient, paradoxical low-flow low-gradient (P-LFLG), and classical LFLG (C-LFLG) groups, respectively, as compared to their controls. CONCLUSIONS: In general, AS patients who survive the first three months after TAVR have a similar survival to their matched controls. Relative survival benefit is the highest in low-to-intermediate risk AS patients with a high transvalvular gradient.
Theut et al. (Sun,) conducted a cohort in Aortic stenosis (n=16,042). Transcatheter aortic valve replacement (TAVR) vs. Age- and sex-matched background population was evaluated on Early mortality (≤90 days) (HR 3.90, 95% CI 2.82-5.39, p=<0.001). TAVR was associated with higher early mortality (≤90 days) compared to matched controls (HR 3.90; 95% CI 2.82-5.39; p<0.001), but late mortality (>90 days) was similar between groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: